Total Payments
$5,510
2024 Payments
$1,369
Companies
36
Transactions
273
Medicare Patients
3,319
Medicare Billing
$280,151
Payment Breakdown by Category
Food & Beverage$4,543 (82.4%)
Travel$943.03 (17.1%)
Education$24.32 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,543 | 269 | 82.4% |
| Travel and Lodging | $943.03 | 3 | 17.1% |
| Education | $24.32 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic USA, Inc. | $1,047 | 5 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $503.74 | 35 | $0 (2022) |
| ABBVIE INC. | $379.59 | 15 | $0 (2024) |
| UCB, Inc. | $374.06 | 23 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $295.62 | 32 | $0 (2022) |
| EMD Serono, Inc. | $281.44 | 18 | $0 (2024) |
| SK Life Science, Inc. | $229.03 | 10 | $0 (2024) |
| Amgen Inc. | $206.42 | 9 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $186.19 | 8 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $170.68 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,369 | 71 | ABBVIE INC. ($259.29) |
| 2023 | $798.64 | 42 | UCB, Inc. ($99.42) |
| 2022 | $786.74 | 60 | Biohaven Pharmaceutical Holding Company Ltd. ($295.62) |
| 2021 | $156.03 | 8 | SK Life Science, Inc. ($53.20) |
| 2020 | $130.87 | 8 | Supernus Pharmaceuticals, Inc. ($130.87) |
| 2019 | $1,242 | 15 | Medtronic USA, Inc. ($1,047) |
| 2018 | $975.20 | 66 | Supernus Pharmaceuticals, Inc. ($202.04) |
| 2017 | $51.74 | 3 | Supernus Pharmaceuticals, Inc. ($28.82) |
All Payment Transactions
273 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Central Nervous System | ||||||
| 12/18/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.74 | General |
| 11/21/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $2.14 | General |
| 10/31/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.16 | General |
| 10/31/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $2.18 | General |
| 10/24/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/23/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $22.99 | General |
| 10/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.33 | General |
| Category: Neuroscience | ||||||
| 10/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $32.26 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Central Nervous System | ||||||
| 10/08/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $34.93 | General |
| Category: Neurology | ||||||
| 10/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Neuropsychiatry | ||||||
| 10/03/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: Neurology | ||||||
| 09/26/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: Neurology | ||||||
| 09/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.63 | General |
| Category: Neuroscience | ||||||
| 09/24/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $17.81 | General |
| 09/21/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $32.89 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Neuropsychiatry | ||||||
| 09/09/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Adenosine A2A Receptors | ||||||
| 09/05/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Central Nervous System | ||||||
| 08/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.86 | General |
| 08/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $2.56 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 529 | 739 | $293,836 | $44,567 |
| 2022 | 11 | 706 | 998 | $372,483 | $65,049 |
| 2021 | 12 | 931 | 1,304 | $363,112 | $81,585 |
| 2020 | 17 | 1,153 | 1,538 | $398,238 | $88,950 |
Total Patients
3,319
Total Services
4,579
Medicare Billing
$280,151
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 268 | 421 | $155,437 | $26,911 | 17.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 45 | 45 | $21,561 | $4,367 | 20.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 59 | 108 | $23,220 | $3,559 | 15.3% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2023 | 34 | 35 | $28,280 | $3,227 | 11.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 43 | 44 | $26,246 | $1,701 | 6.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $4,350 | $1,488 | 34.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 33 | 33 | $19,173 | $1,318 | 6.9% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2023 | 18 | 20 | $10,140 | $1,071 | 10.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 18 | $5,429 | $924.80 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 326 | 534 | $196,996 | $35,672 | 18.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 100 | 100 | $47,913 | $8,842 | 18.5% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2022 | 33 | 36 | $29,088 | $3,574 | 12.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 55 | 95 | $20,425 | $3,255 | 15.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 38 | 39 | $8,892 | $2,993 | 33.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 51 | $7,854 | $2,785 | 35.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $6,045 | $2,273 | 37.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 46 | 46 | $27,439 | $2,033 | 7.4% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2022 | 20 | 20 | $10,140 | $1,109 | 10.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 16 | $4,934 | $900.70 | 18.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 29 | $2,915 | $861.28 | 29.6% |
| 95822 | Measurement of brain wave activity (eeg), in coma or asleep | Facility | 2022 | 15 | 17 | $9,843 | $751.22 | 7.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 320 | 548 | $98,546 | $36,922 | 37.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 114 | 114 | $36,787 | $10,777 | 29.3% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2021 | 56 | 59 | $47,672 | $5,224 | 11.0% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2021 | 93 | 158 | $33,768 | $5,091 | 15.1% |
About Dr. Luis Reina, MD
Dr. Luis Reina, MD is a Neurology healthcare provider based in Lawton, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891891362.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luis Reina, MD has received a total of $5,510 in payments from pharmaceutical and medical device companies, with $1,369 received in 2024. These payments were reported across 273 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($4,543).
As a Medicare-enrolled provider, Reina has provided services to 3,319 Medicare beneficiaries, totaling 4,579 services with total Medicare billing of $280,151. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Lawton, OK
- Active Since 09/15/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1891891362
Products in Payments
- ACTIVA (Device) $1,047
- NURTEC ODT (Drug) $372.41
- OXTELLAR XR (Drug) $338.89
- Briviact (Drug) $208.38
- QULIPTA (Drug) $186.11
- Aimovig (Biological) $174.84
- INGREZZA (Drug) $170.68
- Betaseron (Drug) $157.88
- TROKENDI XR (Drug) $151.18
- ULTOMIRIS (Biological) $149.49
- BOTOX (Biological) $141.88
- ZEPOSIA (Drug) $125.24
- NUPLAZID (Drug) $124.48
- APTIOM (Drug) $120.53
- Austedo XR (Drug) $103.32
- UBRELVY (Drug) $102.69
- VYVGART (Drug) $73.94
- Fycompa (Drug) $70.70
- KESIMPTA (Drug) $70.58
- Nourianz (Drug) $70.14
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.